# A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

> **NCT05748171** · PHASE2 · RECRUITING · sponsor: **Pfizer** · enrollment: 100 (estimated)

## Conditions studied

- ACUTE LYMPHOBLASTIC LEUKEMIA

## Interventions

- **DRUG:** Inotuzumab ozogamicin
- **DRUG:** ALLR3

## Key facts

- **NCT ID:** NCT05748171
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-17
- **Primary completion:** 2033-10-31
- **Final completion:** 2036-11-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05748171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05748171, "A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05748171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*